金山科研平台，产品价格货期咨询微信：jinshanbio Source:Mouse myeloma cell line, NS0-derived, Gln25-Met557 & Ser358-Met557, both with a C-terminal 6-His tag Accession #:AAH36126 N-terminal Sequence Analysis:Gln25 predicted (No result obtained, sequencing might be blocked) & Ser358 Purity:>90%, by SDS-PAGE under reducing conditions and visualized by silver stain. Predicted Molecular Mass:61.3 kDa SDS-PAGE:66-98 kDa & 30-40 kDa, reducing conditions Activity:Measured by its binding ability in a functional ELISA.WhenRecombinant Mouse Glypican 3is coated at5µg/mL (100µL/well), the concentration of recombinant human FGFbasic that produces 50%of the optimal binding response is found to be approximately 0.75 - 3.75 ng/mL. Formulation:Lyophilized from a 0.2 µm filtered solution in PBS.See Certificate of Analysis for details. Molecule Information: Glypican 3 Aliases: GPC3 Entrez Gene IDs: 2719 (Human); 14734 (Mouse); 25236 (Rat) Background: Glypican 3

Mutations in Glypican 3 cause a rare disorder in humans, Simpson-Golabi-Behmel Syndrome, which is characterized by pre- and postnatal overgrowth of multiple tissues and organs and an increased risk for developing embryonic tumors. These features are also present in the mouse knock-out of Glypican 3 indicating that Glypican 3 regulates cell survival and inhibits cell proliferation during development. Glypican 3 has been implicated in regulating many different signaling pathways including: IGF, FGF, BMP and Wnt. An endoproteolytic processing of Glypican 3 by proprotein convertases is required for the modulation of Wnt signaling. Direct interaction of Glypican 3 with FGF-basic has been observed and is mediated by the heparan sulfate chains.